Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009

Jean, Shio Shin; Lee, Wen Sen; Bai, Kuan Jen; Yu, Kwok Woon; Hsu, Chin Wang; Liao, Chun-Hsing; Ko, Wen Chien; Wu, Jiunn Jong; Chen, Yen Hsu; Chen, Yao Shen; Liu, Jien Wei; Lü, Min; Liu, Cheng Yi; Chen, Ray Jade; Hsueh, Po-Ren

doi:10.1016/j.diagmicrobio.2014.09.027

Cited by 6 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Escherichia coli , Klebsiella pneumoniae and Enterobacter cloacae are Gram-negative bacilli which fall in the ESKAPE ( Enterococcus faecium , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumannii , Pseudomonas aeruginosa , and Enterobacter species) group of pathogens and cause serious community or hospital acquired infections [3]. Bacteria becoming resistant to last resort of antibiotics such as carbapenems and colistin make clinical treatment options for infections very limited [4]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model

2018

View full text Add to dashboard Cite

BackgroundPhage therapy is the therapeutic use of bacteriophages to treat highly drug resistant bacterial infections. The current surge in bacteriophage therapy is motivated mainly because of the emergence of antibiotic-resistant bacteria in clinics. This study evaluated the therapeutic potential of three bacteriophages isolated against Escherichia coli ec311, Klebsiella pneumoniae kp235 and Enterobacter cloacae el140 strains using Galleria mellonella. The in vitro activity of three different phages belonging to Podoviridae and Myoviridae families was studied by the double agar overlay method against multi-drug resistant strains. Larval survivability studies were performed to evaluate the potential of phages against infection using G. mellonella.ResultsAll the three phages were found to have potential to infect the host bacterial strains. For in vivo studies it was observed that E. coli and E. cloacae infected larvae, should be treated with three phage doses (20 μL, 104 PFU/mL) at 6 h interval to achieve 100% survival rate. But in the case of K. pneumoniae, a single phage dose treatment showed promising outcome. When mixed bacterial infections (all three bacterial cultures at 108 CFU/mL) were tested, minimum of four doses of phage cocktail (three phages) at 6 h interval was necessary to recover the larvae. All the results were confirmed by enumerating bacteria from the larvae.ConclusionOur data shows that although in vitro studies showed high infectivity of phages, for in vivo models multiple phage doses were required for effective treatment.Electronic supplementary materialThe online version of this article (10.1186/s12866-018-1234-4) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Multi-drug resistance among Enterobacteriaceae is growing at a faster rate than once believed, which results in high mortality rate globally [4]. In order to overcome this problem of resistance a more effective alternative therapeutic option is required.…”

Section: Introductionmentioning

confidence: 99%

The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model

2018

View full text Add to dashboard Cite

show abstract

“…Data (6) shows Polymyxins is a class of cyclic polypeptide antibiotics with strong antibacterial activity against Gram-negative bacteria. However, bacteria are becoming resistant to the last resort of Polymyxins, so that it limits the options of clinical treatment for serious infections (4). Thus, to effectively control serious infections caused by MDR Gramnegative bacteria, the combination of antibiotics may be a better choice.…”

Section: Introductionmentioning

confidence: 99%

In vitro bacteriostatic effects of Polymyxin B combined with Propofol medium and long chain fat emulsion injection against Escherichia coli

Wang

Chen

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Polymyxins is a class of cyclic polypeptide antibiotics with strong antibacterial activity against Gram-negative bacteria. However, bacteria become resistant to Polymyxins. Thus, Polymyxin B (PMB) in combination with other antimicrobials may be a better choice in clinic. This study aimed to evaluate the synergistic bacteriostatic effect of PMB combined with Propofol medium and long chain fat emulsion injection against Escherichia coli in vitro. Methods:The Minimal Inhibitory Concentration of Polymyxin B combined with Propofol medium and long chain fat emulsion injection and two drugs used alone against Escherichia coli were detected with the Kirby-Bauer disk diffusion (K-B) method, and the diameter of the inhibition zone was calculated to evaluate bacteriostatic effects.Results: Different concentrations of PMB all had obvious bacteriostatic effects on Escherichia coli, while different concentrations of Propofol medium and long chain fat emulsion injection had no bacteriostatic effects on Escherichia coli. The bacteriostatic effect of the combination of PMB with Propofol medium and long chain fat emulsion injection against Escherichia coli was synergistic, and no effects of uncorrelated and antagonism were observed in this combination.Conclusions: PMB combined with Propofol medium and long chain fat emulsion injection can improve the bacteriostatic effect for Escherichia coli in vitro.

show abstract

Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018

Jean

Lee

Liu

et al. 2022

Journal of Microbiology, Immunology and Infection

View full text Add to dashboard Cite

Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009

Cited by 6 publications

References 28 publications

The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model

The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model

In vitro bacteriostatic effects of Polymyxin B combined with Propofol medium and long chain fat emulsion injection against Escherichia coli

Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018

Contact Info

Product

Resources

About